Joseph Brent Muhlestein, MD, FAHA, FACC

Original Contribution

Nickel Elution Properties of Contemporary Interatrial Shunt Closure Devices

02/01/2015

Joseph Brent Muhlestein , MD, FAHA, FACC;

Anwar Tandar , MD;

Divya Ratan Verma , MD, MS;

Namakkal S. Rajasekaran , PhD;

Renee Neuharth , BS ;

Amit N. Patel , MD, MS;

Rodney S. Badger , MD;

We sought to compare nickel elution properties of contemporary interatrial shunt closure devices in vitro. There is substantial variability in nickel elution; the safety of low nickel elution devices in patients with nickel allergy needs to...

We sought to compare nickel...

02/01/2015

Journal of Invasive Cardiology

The Movement to Short-Infusion Tirofiban in the Cath Lab: the Next Leap in Practice Change

03/01/2018

Joseph Brent Muhlestein , MD, FAHA, FACC;

If patients are not already on dual antiplatelet therapy when they come in, achieving that status is going to take time and there is going to be a window in which they are not protected. One of the advantages of the short-term infusion of...

If patients are not already on...

03/01/2018

Cath Lab Digest

Economics and Care

Switching From Eptifibatide to Tirofiban Use in ACS: Reducing Cost While Maintaining Quality of Care

02/26/2015

Joseph Brent Muhlestein , MD, FAHA, FACC;

An emphasis on consensus and partnership allows Intermountain Health Care to unite under treatment guidelines, establish protocols, and save money, all while providing quality patient care.

An emphasis on consensus and...

02/26/2015

Cath Lab Digest

Why it is Important to Test Platelet Reactivity

04/04/2013

Joseph Brent Muhlestein , MD, FAHA, FACC;

In acute coronary syndrome (ACS) patients who receive stents in the cath lab, studies have demonstrated that if there is an inadequate amount of platelet inhibition despite the administration of dual antiplatelet therapy, many of these...

In acute coronary syndrome (ACS)...

04/04/2013

Cath Lab Digest

The Short-Term Aggrastat Infusion Registry (STAIR): Evaluating the Safety and Efficacy of Heparin + Short-Term Tirofiban vs Bivalirudin in PCI

09/05/2019

Joseph Brent Muhlestein , MD, FAHA, FACC;

We compared patients with coronary artery disease who underwent PCI having received either scheduled, planned tirofiban with short-term infusion or planned bivalirudin, which most of the time was without any use of a GP IIb/IIIa receptor...

We compared patients with...

09/05/2019

Cath Lab Digest

Original Contribution

Real-World Safety and Efficacy of Glycoprotein IIb/IIIa Inhibitors
during Percutaneous Coronary Intervention

08/01/2008

Jeffrey L. Anderson , MD;

Joseph Brent Muhlestein , MD, FAHA, FACC;

Peter J. Casterella , MD;

James R. Revenaugh , MD;

James L. Burke , MD;

Robert R. Pearson , BS;

Tami L. Bair , BS;

Heidi T. May , MSPH, PhD;

Benjamin Horne , PhD, MPH;

Percutaneous coronary intervention (PCI) is commonly employed in the management of patients with coronary artery disease (CAD), but the optimal adjunctive pharmacologic strategy for patients undergoing PCI is a frequently debated issue,...

Percutaneous coronary...

08/01/2008

Journal of Invasive Cardiology